Novo Nordisk A/S : Share repurchase programme

2014.
Under the programme initiated 30 January 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.6 billion in the period from 30 January 2014 to 29 April 2014.
Since the announcement as of 1 April 2014, the following transactions have been made under the programme:

1 April 2014 265,000 244.81 64,875,074

2 April 2014 215,000 245.52 52,786,779

3 April 2014 230,000 245.30 56,418,103

4 April 2014 220,000 243.26 53,517,662

With the transactions stated above, Novo Nordisk owns a total of 115,131,901 B shares of DKK 0.20, corresponding to 4.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,750,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 4 April 2014, Novo Nordisk has

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 23 / 2014

Page 2 of 2

repurchased a total of 11,811,995 B shares equal to a transaction value of DKK
2,840,878,689.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B

shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 23 / 2014

distributed by